– UK, Stevenage – Freeline Therapeutics Holdings plc (NASDAQ: FRLN), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced the appointment of Dr. Colin Love, Ph.D., to its Board of Directors, effective immediately.
Dr. Love has over 30 years of experience leading biopharmaceutical company operations, including the development and launch of several biotechnology products.
“We are delighted to welcome Colin Love to Freeline’s Board of Directors,” said CEO, Theresa Heggie. “His appointment comes at a key time as Freeline evolves into its next stage of growth, including the development, production and potential commercialization of the Company’s pipeline. Colin’s extensive experience in manufacturing complex biotechnology products will be valuable as we continue to advance our mission to bring functional gene therapy cures to patients with hemophilia, Fabry and Gaucher diseases, as well as other serious disorders.”
About Dr. Colin Love
Dr. Love brings more than three decades of experience developing, manufacturing, and launching biotechnology products. He currently is the COO and a co-founder of Replimune, a biotechnology company developing oncolytic immunotherapies, where he has served since 2015. Since December 2014, he has provided consultancy support to a range of life science companies, from small gene therapy start-ups to large established biotechnology companies, including Amgen.
From 2011 to 2014, Dr. Love was a VP, Clinical Operations at Amgen, where he was responsible for the two sites developing and manufacturing T-VEC, an oncolytic virus therapy approved by the FDA and EMA in 2015. Dr. Love was previously SVP, Product Development at BioVex Group, Inc., a privately-held biotechnology company developing T-VEC, from 2000 to 2011 until its acquisition by Amgen.
Before joining BioVex, he held leadership positions in manufacturing and development at Celltech plc from 1992 to 2000 and led development teams for Medeva plc, Serono Diagnostics, and Amersham International.
“I am very pleased to be joining Freeline’s Board of Directors at this exciting time,” said Dr. Love. “The Company has the potential to deliver a revolutionary approach to treating rare diseases with single-dose gene therapies that offer patients the hope of long-term curative results. I look forward to working with the Freeline team to deliver on this mission.”
Dr. Love holds a Ph.D. in Biochemistry from the University of Glasgow.
About Freeline Therapeutics
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient’s bloodstream. Freeline’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing, and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline, is headquartered in the UK and has operations in Germany and the US.
For more information : https://www.freeline.life/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
